drugset / Trial / NCT03716583

Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer

NCT03716583

Phase 2 Completed 48 enrolled Dennis Bregner Zetner
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of the present randomized double-blinded placebo-controlled clinical trial is to investigate if melatonin can protect against acute radiation dermatitis in patients with early breast cancer receiving radiation therapy, and whether this has an impact on the patients' quality of life.

Timeline

Start
2019-04-30
Primary completion
2021-01-31
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 25 mg Topical
Subject dimethyl sulfoxide Small molecule 150 mg Topical